Director/PDMR Shareholding
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms E Walmsley |
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£0.0000 |
12,482 (Deferred) |
|
||
|
|
£0.0000 |
8,614 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
21,096 £0.0000 |
||||
|
e) |
Date of the transaction |
2018-02-16 |
|||
|
f) |
Place of the transaction
|
n/a |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms E Walmsley |
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.1563 |
5,868 (Deferred) |
|
||
|
|
£13.1563 |
4,050 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
9,918 £13.1563 |
||||
|
e) |
Date of the transaction |
2018-02-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr R Connor |
|||
|
b) |
Position/status |
President, Global Manufacturing & Supply |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£0.0000 |
9,142 (Deferred) |
|
||
|
|
£0.0000 |
6,308 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
15,450 £0.0000 |
||||
|
e) |
Date of the transaction |
2018-02-16 |
|||
|
f) |
Place of the transaction
|
n/a |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|
||||
|
a) |
Name |
Mr R Connor |
|
|||
|
b) |
Position/status |
President, Global Manufacturing & Supply |
|
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
||||
|
a) |
Name |
GlaxoSmithKline plc |
|
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
|
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
£13.1028 |
4,384 (Deferred) |
|
|||
|
|
£13.1200 |
3,026 (Matching) |
|
|||
|
|
|
|
|
|||
|
d) |
Aggregated information |
|
|
|||
|
Aggregated volume Price |
7,410 £13.1114 |
|
||||
|
e) |
Date of the transaction |
2018-02-16 |
|
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr S Dingemans |
|||
|
b) |
Position/status |
Chief Financial Officer |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£0.0000 |
17,435 (Deferred) |
|
||
|
|
£0.0000 |
12,030 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
29,465 £0.0000 |
||||
|
e) |
Date of the transaction |
2018-02-16 |
|||
|
f) |
Place of the transaction
|
n/a |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|
||||
|
a) |
Name |
Mr S Dingemans |
|
|||
|
b) |
Position/status |
Chief Financial Officer |
|
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
||||
|
a) |
Name |
GlaxoSmithKline plc |
|
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
|
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
£13.1236 |
8,360 (Deferred) |
|
|||
|
|
£13.1230 |
5,768 (Matching) |
|
|||
|
|
|
|
|
|||
|
d) |
Aggregated information |
|
|
|||
|
Aggregated volume Price |
14,128 £13.1233 |
|
||||
|
e) |
Date of the transaction |
2018-02-16 |
|
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr N Hirons |
|||
|
b) |
Position/status |
SVP, Global Ethics and Compliance |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£0.0000 |
6,402 (Deferred) |
|
||
|
|
£0.0000 |
4,418 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
10,820 £0.0000 |
||||
|
e) |
Date of the transaction |
2018-02-16 |
|||
|
f) |
Place of the transaction
|
n/a |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|
||||
|
a) |
Name |
Mr N Hirons |
|
|||
|
b) |
Position/status |
SVP, Global Ethics and Compliance |
|
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
||||
|
a) |
Name |
GlaxoSmithKline plc |
|
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
|
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
£13.1068 |
3,070 (Deferred) |
|
|||
|
|
£13.1118 |
2,120 (Matching) |
|
|||
|
|
|
|
|
|||
|
d) |
Aggregated information |
|
|
|||
|
Aggregated volume Price |
5,190 £13.1093 |
|
||||
|
e) |
Date of the transaction |
2018-02-16 |
|
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr D Redfern |
|||
|
b) |
Position/status |
Chief Strategy Officer |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£0.0000 |
10,258 (Deferred) |
|
||
|
|
£0.0000 |
7,078 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
17,336 £0.0000 |
||||
|
e) |
Date of the transaction |
2018-02-16 |
|||
|
f) |
Place of the transaction
|
n/a |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|
||||
|
a) |
Name |
Mr D Redfern |
|
|||
|
b) |
Position/status |
Chief Strategy Officer |
|
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
||||
|
a) |
Name |
GlaxoSmithKline plc |
|
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
|||
|
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
|
£13.1800 |
4,822 (Deferred) |
|
|||
|
|
£13.1800 |
3,328 (Matching) |
|
|||
|
|
|
|
|
|||
|
d) |
Aggregated information |
|
|
|||
|
Aggregated volume Price |
8,150 £13.1800 |
|
||||
|
e) |
Date of the transaction |
2018-02-16 |
|
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms C Thomas |
|||
|
b) |
Position/status |
SVP, Human Resources |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£0.0000 |
13,805 (Deferred) |
|
||
|
|
£0.0000 |
9,525 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
23,330 £0.0000 |
||||
|
e) |
Date of the transaction |
2018-02-16 |
|||
|
f) |
Place of the transaction
|
n/a |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Ms C Thomas |
|||
|
b) |
Position/status |
SVP, Human Resources |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.1180 |
6,489 (Deferred) |
|
||
|
|
£13.1180 |
4,478 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
10,967 £13.1180 |
||||
|
e) |
Date of the transaction |
2018-02-16 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr P Thomson |
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£0.0000 |
4,689 (Deferred) |
|
||
|
|
£0.0000 |
3,235 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
7,924 £0.0000 |
||||
|
e) |
Date of the transaction |
2018-02-19 |
|||
|
f) |
Place of the transaction
|
n/a |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Mr P Thomson |
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.1240 |
2,204 (Deferred) |
|
||
|
|
£13.1240 |
1,521 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
3,725 £13.1240 |
||||
|
e) |
Date of the transaction |
2018-02-19 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr P Vallance |
|||
|
b) |
Position/status |
Outgoing President, R&D |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£0.0000 |
20,322 (Deferred) |
|
||
|
|
£0.0000 |
14,022 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
34,344 £0.0000 |
||||
|
e) |
Date of the transaction |
2018-02-19 |
|||
|
f) |
Place of the transaction
|
n/a |
|||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
Dr P Vallance |
|||
|
b) |
Position/status |
Outgoing President, R&D |
|||
|
c) |
Initial notification/ amendment |
Initial Notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GlaxoSmithKline plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b) |
Nature of the transaction |
The sale of Ordinary Shares following the exercise of options on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. |
|||
|
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£13.1760 |
20,322 (Deferred) |
|
||
|
|
£13.1760 |
14,022 (Matching) |
|
||
|
|
|
|
|
||
|
d) |
Aggregated information |
|
|||
|
Aggregated volume Price |
34,344 £13.1180 |
||||
|
e) |
Date of the transaction |
2018-02-19 |
|||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
This information is provided by RNS
Latest directors dealings
- 1 day ago Judges Scientific
- 1 day ago Mitie Group
- 1 day ago NCC Group
- 1 day ago Worldwide Healthcare Trust
- 1 day ago JpMorgan China Growth & Income